Atomic bomb survivors are a population suitable for studying the relationship between somatic mutation and cancer risk because their exposure doses are relatively well known and their dose responses in terms of cancer risk have also been thoroughly studied. An analysis has been made of erythrocyte glycophorin A (GPA) gene mutations in 1,226 atomic bomb survivors in Hiroshima and Nagasaki. The GPA mutation frequency (Mf) increased slightly but significantly with age at the time of measurement and with the number of cigarettes smoked. After adjustment for the effect of smoking, the Mf was significantly higher in males than in females and higher in Hiroshima than in Nagasaki. All of these characteristics of the background GPA Mf were in accord with those of solid tumor incidence obtained from an earlier epidemiological study of A-bomb survivors. Analysis of the dose effect on Mf revealed the doubling dose to be about 1.20 Sv and the minimum dose for detection of a significant increase to be about 0.24 Sv. No significant dose effect for difference in sex, city, or age at the time of bombing was observed. Interestingly, the doubling dose for the GPA Mf approximated that for solid cancer incidence (1.59 Sv). And the minimum dose for detection was not inconsistent with the data for solid cancer incidence. The dose effect was significantly higher in those diagnosed with cancer before or after measurement than in those without a history of cancer. These findings are consistent with the hypothesis that somatic mutations are the main cause of excess cancer risk from radiation exposure. Environ Health Perspect 1 04(Suppl 3): 493-496 (1996) 
Introduction
As knowledge in the molecular biology of cancer accumulates, the field of cancer risk evaluation is gaining attention. Analysis of oncogenes and tumor suppressor genes has demonstrated that mutations such as base substitutions, deletions, recombinations, and amplification of DNA are crucial for carcinogenesis (1) .
The monitoring of somatic mutations in vivo can be a biological marker useful in evaluating the cancer risk from exposure to environmental mutagens (2) . Several somatic mutation assays have been established for the glycophorin A (GPA) genes in erythrocytes (3, 4) and for the hypoxanthine phosphoribosyltransferase (hprt) (5,6), HLA-A (7, 8) , and TcRa and P genes (9, 10) (4, 11, 12) , and the TcR assay has potential value as a biological dosimeter for those experiencing recent or chronic radiation exposure (13, 14) .
Populations such as atomic bomb (A-bomb) survivors and persons who were administered the radioactive medical contrast agent Thorotrast are suitable for studying the relationship between somatic mutations and cancer risk. Their radiation doses are relatively well known and epidemiological monitoring has been extensive (15, 16) . In this report, we will summarize the results among A-bomb survivors using the erythrocyte GPA mutation assay for biologically substantiating estimated radiation doses and epidemiologically derived risk estimates. Among these four types of mutants, we will report here the precise analysis of hemizygous mutant frequencies (M).
Materials and Methods Subject
The analysis used here was based on weighted bone marrow doses (19) (20) .
The GPA Mf was fairly stable for individuals during the 5-year study period, but a cross-sectional analysis showed an agerelated increase of the Mf in persons ranging from 40 to 90 years old. This may represent a long-term accumulation of mutations in bone marrow stem cells, which is similar to the age-related differences in somatic Mfs also reported for other gene loci in T cells (8, 9) . The induction and decay rates of in vivo mutant cells must be taken into account when considering the magnitude of the age-dependent increase of mutations (21) . Dose Response of D-type Mutant Frequency GPA-NO and GPA-MO Mfs were significantly correlated (R= 0.34; p < 0.001). Figure 1 shows the dose-response curve of the GPA D-type Mf for about 1, 200 survivors using the estimated dose to bone marrow (BM), based on the Dosimetry System 1986 (DS86) and assuming a neutron relative biological effectiveness of 10 . Figure IA shows a linear dose-response curve, excluding outliers whose Mf and dose were more than 400 x 106 and 5 Sv, respectively. Figure 1 B shows the cubic analysis of log-log transformed data without excluding the outliers. We used a log transformation for both GPA Mf and BM dose because the skewness of both variables gave unduly high influence to a small number of points utliers. In addition, log transformation of dose can equalize the effect of dose-estimation error on the dose response throughout the range of doses. In both statistical analyses, Mf increases significantly with increase of BM dose; however, a purely cubic model best fit these data. This implies that the initial slope of the doseresponse curve on the log-log scale is 0. On the untransformed scale ( Figure IA) , the log-log cubic dose response flattens out considerably, resembling a linear doseresponse model. Interestingly, the ratio of the GPA Mf in persons exposed to 1 Sv to the controls is 1.87, which is close to the relative risk of solid-tumor incidence at 1 Sv (1.63) (15 dose of the GPA Mf was also close to that of solid-cancer incidence in A-bomb survivors (1.59 Sv) (15) , and the minimum detection dose for the GPA Mf was not inconsistent with the data for solid-cancer risk in the low-dose groups of survivors, i.e., the point at which the relative risk for those exposed in the 0.200 to 0.499 Sv range first becomes significantly higher than 1 (22, 23) . These observations of dose response are consistent with the hypothesis that radiation-induced somatic cell mutations are the major cause of excess cancer risks after radiation exposure.
In this context, we analyzed the GPA Mf of patients with cancers. Figure 2 shows among Hiroshima survivors the dose responses of the GPA D-type Mf for 81 subjects previously or subsequently diagnosed with cancer and for 548 subjects with neither malignant nor benign tumors. Statistical analysis using the log-log cubic model revealed that the dose effect of D-type Mf was significantly higher in those diagnosed with cancer before or after measurement than in those without a history of cancer (p < 0.009). The ratio of these dose responses is about 2.3 at 5 Sv.
Thus, a higher frequency of mutations may contribute to the development of cancer, or the cancer group may be more sensitive to radiation. In either case, the possibility of dosimetry error must be considered, too (14, (25) (26) (27) , and Fanconi's anemia (25) . In addition, among many Thorotrast patients who are at high risk of developing malignant tumors and leukemia (16), the Mf is significantly higher (13, 14) . Thus, we have proposed that the GPA Mf can be used as a biomarker for the assessment of cancer risk among radiation-exposed people. Finally, understanding the interaction between ionizing radiation and other suspected causes of cancer is critical to human cancer-risk assessment. The possible interactive effects of radiation exposure and tobacco smoking on GPA Mf in those with cancer versus persons without cancer should be examined in the future. Lower GPA Mf in females suggests the possible effect of sex hormones on either hemopoietic stem-cell proliferation rates or survival of GPA mutant cells. Continuing somaticmutation studies of the A-bomb survivors and clinical and epidemiological follow-up of survivors whose Mf is high may one day darify whether the GPA mutation assay is a suitable end point for predicting cancer risk.
